Immunotherapy最新文献_第3页

Safety and tolerability of a new intravenous immunoglobulin 10% in patients with primary immunodeficiency. 一种新的静脉注射免疫球蛋白10%对原发性免疫缺陷患者的安全性和耐受性。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-08-07 DOI: 10.1080/1750743X.2026.2706964

Roberto Crea, Elena Perez, Chaim M Roifman

{"title":"Safety and tolerability of a new intravenous immunoglobulin 10% in patients with primary immunodeficiency.","authors":"Roberto Crea, Elena Perez, Chaim M Roifman","doi":"10.1080/1750743X.2026.2706964","DOIUrl":"10.1080/1750743X.2026.2706964","url":null,"abstract":"Aims: Kedrion IVIg 10% (KIg10; QIVIGY) is a new, ready-to-use, 10% liquid IVIg (100 mg/mL) approved for adults with primary immunodeficiency (PI). This report presents safety and tolerability data from a phase III study.Methods: This was an open-label, prospective, single-arm, historically controlled, multicenter study in adults with confirmed PI receiving commercially available IVIg products. Participants received KIg10 200-800 mg/kg once every 21 or 28 days for 17 and 13 infusions, respectively.Results: Forty-seven participants received KIg10 every 21 days (n = 8) or every 28 days (n = 39). Overall, 97.9% (n = 46) of participants had treatment-emergent adverse events (TEAEs) and 46.8% (n = 22) experienced drug-related TEAEs; most were mild or moderate. Across 80 infusions, 122 infusional AEs occurred in 30 participants (63.8%); infusional AEs decreased with later versus initial infusions. No life-threatening TEAEs, deaths, serious or severe drug-related TEAEs, thrombotic events, or occurrences of aseptic meningitis, transfusion-related acute lung injury, acute renal failure, or neutropenia were observed. A drug-related hypersensitivity event (skin reaction) occurred in 1 participant. Forty-four (93.6%) participants reached the maximum dose rate (8 mg/kg/min).Conclusion: KIg10 was well tolerated in adults with PI, supporting its use as a replacement therapy option in this population.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"825-833"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148684377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions. 狼疮性肾炎治疗：近期荟萃分析和未来方向的综合概述。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-07-18 DOI: 10.1080/1750743X.2026.2705727

Feigao Li, Xizhe Liu, Bokun Chen, Menghao Li, Xiuju Liu

{"title":"Lupus nephritis treatment: a comprehensive overview of recent meta-analyses and future directions.","authors":"Feigao Li, Xizhe Liu, Bokun Chen, Menghao Li, Xiuju Liu","doi":"10.1080/1750743X.2026.2705727","DOIUrl":"10.1080/1750743X.2026.2705727","url":null,"abstract":"Introduction: This review summarizes recent findings from meta-analyses on lupus nephritis (LN) therapies to promote precision medicine and address the challenge of fragmented evidence.Methods: A literature search identified 34 relevant meta-analyses published between January 2021 and March 2025.Results: Key findings include: Biological agents, particularly Belimumab and Obinutuzumab, significantly improve complete renal remission (CR) and reduce the risk of end-stage renal disease, breaking through traditional therapeutic bottlenecks. However, rituximab, while effective, carries a higher infection risk (SUCRA = 74.98%). The combination of tacrolimus and mycophenolate mofetil doubled the CR rate compared to monotherapy (OR = 2.85), but requires monitoring for creatinine elevation. Voclosporin use is limited by a high infection risk. The combination of Tripterygium glycosides and Western medicine increased the CR rate by 61% (RR = 1.61), while Astragalus-containing Chinese herbal medicine significantly reduced proteinuria (SMD = 0.51), highlighting the value of traditional Chinese medicine in enhancing efficacy and reducing toxicity. Glucocorticoid therapy presents a critical trade-off: an initial dose >60 mg/day improves CR to 34.6% but elevates severe infection and mortality rates to 12.1% and 2.7%, respectively, underscoring the urgent need for dose precision. In diagnostics, urinary TWEAK demonstrates high specificity. Mesenchymal stem cell therapy achieved a 33.7% remission rate.Conclusion: In conclusion, this review provides a comprehensive overview of recent research on LN treatment, offering evidence-based support for clinical decision-making and points out directions for future research.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"847-862"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148497469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer. 免疫疗法对早期非小细胞肺癌、黑色素瘤和结直肠癌治疗的影响。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-08-24 DOI: 10.1080/1750743X.2026.2721165

Alfredo Tartarone, Raffaele Conca, Alessandra Perrone, Rosa Lerose

{"title":"Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer.","authors":"Alfredo Tartarone, Raffaele Conca, Alessandra Perrone, Rosa Lerose","doi":"10.1080/1750743X.2026.2721165","DOIUrl":"10.1080/1750743X.2026.2721165","url":null,"abstract":"In recent years, immunotherapy (I-O), following the introduction into clinical practice of several immune checkpoint inhibitors (ICIs), has revolutionized the treatment landscape of many types of cancer. To date, different ICIs, administered either as monotherapy or in combination with other agents, have been approved or are currently being tested for the treatment of more than 20 different cancer types, mainly in the metastatic setting. More recently, driven by the results achieved in advanced disease, I-O has expanded into the treatment of various tumors at earlier stages, showing promising results also in this context. I-O‑based combination regimens could be particularly effective in early-stage cancer due to different reasons such as the presence of a less immunosuppressive microenvironment, a more intact lymphatic-vascular architecture, a better T-cell fitness, a less tumor heterogeneity and resistance. We reviewed the role of I-O in early-stage non-small cell lung cancer, colorectal cancer, and melanoma with the aim of highlighting the potential advantages of I-O administration in this clinical setting. A comprehensive literature search was conducted using PubMed, Embase, and Web of Science for English language peer-reviewed articles published until June 2026.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"871-881"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540195/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoantigen in cancer immunotherapy: mechanism, therapeutic strategies and future perspectives. 肿瘤免疫治疗中的新抗原：机制、治疗策略及未来展望。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-08-22 DOI: 10.1080/1750743X.2026.2721185

Aditya Raj, Zuber Khan, Mumtaz, Sidharth Mehan, Tapan Lamba, Niyati Pandoh, Keerti Dayal

{"title":"Neoantigen in cancer immunotherapy: mechanism, therapeutic strategies and future perspectives.","authors":"Aditya Raj, Zuber Khan, Mumtaz, Sidharth Mehan, Tapan Lamba, Niyati Pandoh, Keerti Dayal","doi":"10.1080/1750743X.2026.2721185","DOIUrl":"10.1080/1750743X.2026.2721185","url":null,"abstract":"Neoantigens are tumor-specific antigens resulting from genetic, transcriptomic, and proteomic changes, making them a promising avenue for personalized cancer immunotherapy due to their unique specificity and strong immunogenicity. They arise through various mechanisms like SNVs, INDELs, SVs, alternative splicing, post-translational modifications, and viral oncoproteins. Neoantigen-based therapies, including personalized vaccines, adoptive T-cell therapies, and immune checkpoint inhibitors, have demonstrated considerable potential in both preclinical and clinical settings. Tumors with high mutational burdens, like melanoma and lung cancers, show significant neoantigen-driven immune responses. Progress in cancer treatment is highlighted by the need for combinatorial approaches in tumors with low neoantigen loads, such as pancreatic and prostate cancers, to boost immunogenicity. Advances in computational tools and next-generation sequencing support accurate neoantigen identification for personalized therapies. However, challenges remain, including tumor heterogeneity and immune evasion. Innovative solutions such as machine learning for neoantigen prediction and the use of lipid nanoparticles, alongside radiotherapy and chemotherapy, are being developed to overcome these limitations. Future strategies may involve integrating multi-omics data, next-generation vaccines, and CRISPR-Cas9 gene editing technologies to enhance therapeutic precision. Overall, despite existing challenges, neoantigen-targeted immunotherapies hold promise for advancing precision oncology and improving patient outcomes.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"883-908"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of artificial intelligence in predicting immunotherapy treatment outcomes based on gut microbiota composition in cancer patients: a meta-analysis. 人工智能在预测癌症患者肠道微生物群组成的免疫治疗结果中的作用：一项荟萃分析。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-08-20 DOI: 10.1080/1750743X.2026.2717074

Leen Alhassan, Bassel Alrabadi, Suhel F Batarseh, Yousef Alghzawi, Natalie Bandak, Aseel Badwan, Hadeel Al Kayed

{"title":"The role of artificial intelligence in predicting immunotherapy treatment outcomes based on gut microbiota composition in cancer patients: a meta-analysis.","authors":"Leen Alhassan, Bassel Alrabadi, Suhel F Batarseh, Yousef Alghzawi, Natalie Bandak, Aseel Badwan, Hadeel Al Kayed","doi":"10.1080/1750743X.2026.2717074","DOIUrl":"10.1080/1750743X.2026.2717074","url":null,"abstract":"Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but response varies across patients. Gut microbiota may influence immunotherapy outcomes, while artificial intelligence (AI) can help characterize complex microbiome-host interactions. This systematic review and meta-analysis evaluated AI models for predicting immunotherapy outcomes using gut microbiota data.Methods: PubMed, Scopus, and Cochrane Library were searched through January 2025. The primary outcome was pooled area under the curve (AUC).Results: Nine studies were included in the systematic review, with eight eligible for meta-analysis. The pooled AUC was 0.85 (95% CI: 0.78-0.91), indicating strong predictive performance. Several studies identified microbial taxa, including Bacteroides and Porphyromonadaceae, associated with treatment outcomes.Conclusion: AI-based models show promising potential for predicting immunotherapy response using gut microbiota data. However, limited evidence, substantial methodological heterogeneity, and restricted patient populations limit the reliability and generalizability of current estimates. Larger multicenter studies with standardized AI pipelines and external validation are needed before clinical implementation.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"863-870"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148792448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of sublingual immunotherapy with dust mite drops on ECP, TARC, VCAM-1 inflammatory status in patients with allergic rhinitis. 尘螨滴剂舌下免疫治疗对变应性鼻炎患者ECP、TARC、VCAM-1炎症状态的影响

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-08-04 DOI: 10.1080/1750743X.2026.2704434

Bangyu Deng, Yunxia Zhao, Jisheng Liu

{"title":"Impact of sublingual immunotherapy with dust mite drops on ECP, TARC, VCAM-1 inflammatory status in patients with allergic rhinitis.","authors":"Bangyu Deng, Yunxia Zhao, Jisheng Liu","doi":"10.1080/1750743X.2026.2704434","DOIUrl":"10.1080/1750743X.2026.2704434","url":null,"abstract":"Objective: To evaluate the effect of sublingual immunotherapy with dust mite drops on serum eosinophil cationic protein (ECP), thymus and activation-regulated chemokine (TARC), vascular cell adhesion molecule-1 (VCAM-1) levels and symptom improvement in allergic rhinitis (AR) patients.Methods: A prospective randomized controlled trial enrolled 300 AR patients sensitized to dust mites, randomly assigned to control group (conventional treatment, n = 150) and research group (conventional treatment plus sublingual dust mite drops, n = 150) for 6 months.Results: Compared with controls, the research group showed significantly greater reductions in interleukin-4 (IL-4), interleukin-17 (IL-17), ECP, TARC, VCAM-1, lower adverse reaction rates, improved pulmonary function including forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), FEV1/FVC ratio, and small airway function including maximal mid-expiratory flow (MMEF), expiratory flow rate at 50% of FVC (MEF50), expiratory flow rate at 25% of FVC (MEF25), as well as reduced symptom scores (all p < 0.05).Conclusion: Sublingual immunotherapy with Dust mite drops appears effective in suppressing systemic inflammation, minimizing treatment-related adverse events, enhancing both small airway and pulmonary function, and easing the clinical manifestations of allergic rhinitis.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"813-823"},"PeriodicalIF":2.3,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13540133/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148669362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Making dietary modification in the immunotherapy Era: from mechanistic evidence to practical implementation. 免疫治疗时代的饮食改变：从机制证据到实际实施。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-07-01 Epub Date: 2026-08-14 DOI: 10.1080/1750743X.2026.2717073

Parham Habibzadeh, Drew Hurd, Diwakar Davar

引用次数: 0

Exploring the potential of HVJ-E for cancer immunotherapy. 探索HVJ-E在癌症免疫治疗中的潜力。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-09 DOI: 10.1080/1750743X.2026.2697678

Akikazu Harada, Keisuke Nimura

{"title":"Exploring the potential of HVJ-E for cancer immunotherapy.","authors":"Akikazu Harada, Keisuke Nimura","doi":"10.1080/1750743X.2026.2697678","DOIUrl":"10.1080/1750743X.2026.2697678","url":null,"abstract":"HVJ-Envelope (HVJ-E), an inactivated particle derived from the Hemagglutinating virus of Japan, represents a unique virus-based approach for cancer immunotherapy. Unlike replication-competent oncolytic viruses, which exert antitumor effects through viral propagation and tumor cell lysis, HVJ-E lacks replicative capacity and pathogenicity because its viral genome is fragmented. Conversely, although most non-replicative viral vectors are designed primarily as delivery vehicles, HVJ-E itself possesses intrinsic antitumor activity. By preserving the native viral structure and membrane-fusion capacity of the parental virus, HVJ-E enables fragmented viral genomes to enter target cells, thereby inducing antitumor immune activation and tumor cell death. Mechanistic studies have shown that HVJ-E promotes dendritic cell maturation, activates natural killer cells, and stimulates cytotoxic T lymphocytes, leading to systemic antitumor immunity. Clinical trials have demonstrated favorable safety profiles and encouraging signs of efficacy. Furthermore, reverse translational research has identified combination strategies with T cell co-stimulatory signaling and the apolipoprotein system as a downstream mediator that enhances sensitivity to immune attack. This review summarizes the historical development, mechanistic insights, and emerging therapeutic concepts of HVJ-E as a novel cancer immunotherapy platform. A comprehensive literature search was conducted using PubMed for articles related to HVJ-E and cancer published between 2002 and 2025.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"677-693"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The long-term effectiveness of specific immunotherapy in cat allergy: a real-life study. 特异性免疫疗法对猫过敏的长期有效性：一项现实生活中的研究。

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-12 DOI: 10.1080/1750743X.2026.2700927

Nilay Orak Akbay, Dilşad Mungan, Betül Ayşe Sin

{"title":"The long-term effectiveness of specific immunotherapy in cat allergy: a real-life study.","authors":"Nilay Orak Akbay, Dilşad Mungan, Betül Ayşe Sin","doi":"10.1080/1750743X.2026.2700927","DOIUrl":"10.1080/1750743X.2026.2700927","url":null,"abstract":"Aims: Cat allergy has emerged as a significant health concern, particularly for individuals with persistent allergic rhinitis and/or asthma. We aimed to assess the long-term efficacy of immunotherapy with cat allergen.Patients & methods: 41 patients who received cat SCIT were included. Long-term follow-up data were obtained from 22 of 41 patients who could be contacted after completion of immunotherapy.Results: Among 41 patients, 35 were female and six were male, with a median age of 35 years (IQR: 31-42). The median time after stopping AIT was 51.5 months (IQR 32.5). In the 22 patients available for long-term follow-up, the overall mean score of the RQLQ improved to 1.76 ± 1.33 from 3.52 ± 1.23 after AIT (p <0.001). AQLQ scores significantly improved in 13/16 (81.3%) patients diagnosed with asthma (p = 0.02). The visual analog score for rhinitis symptoms decreased after AIT (p = 0.001). In total, 12 of 41 patients (29.3%) experienced a local injection site reaction, two (4.9%) of them had severe asthma worsening and two (4.9%) had a systemic reaction.Conclusion: Our findings suggest that allergen-specific immunotherapy (AIT) is effective in improving symptoms of rhinitis and asthma in patients with cat dander allergy. It also provides sustained clinical benefit in patients who can be evaluated in long-term follow-up; however, larger studies are needed.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"647-656"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study. pembrolizumab治疗尿路上皮癌患者阿片类药物使用的临床影响：单中心回顾性研究

IF 2.3 4区医学

Immunotherapy Pub Date : 2026-06-01 Epub Date: 2026-07-15 DOI: 10.1080/1750743X.2026.2702265

Yusuke Ishigami, Masaya Takahashi, Hitomi Nakatsukasa, Masahito Shibano, Minoru Kato, Kanae Takahashi, Junji Uchida, Yasutaka Nakamura, Hiroyasu Kaneda

{"title":"Clinical impact of opioid use in patients with urothelial carcinoma treated with pembrolizumab: a single center retrospective study.","authors":"Yusuke Ishigami, Masaya Takahashi, Hitomi Nakatsukasa, Masahito Shibano, Minoru Kato, Kanae Takahashi, Junji Uchida, Yasutaka Nakamura, Hiroyasu Kaneda","doi":"10.1080/1750743X.2026.2702265","DOIUrl":"10.1080/1750743X.2026.2702265","url":null,"abstract":"Background: Opioids may influence anti-programmed cell death-1/programmed death-ligand 1 antibody efficacy through effects on the gut microbiome and immune function. Although reduced efficacy has been suggested in non-small cell lung cancer, the impact of opioid use in urothelial carcinoma remains unclear. This study examined the impact of opioids on pembrolizumab efficacy in patients with urothelial carcinoma.Methods: We conducted a retrospective cohort study of patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab at our hospital between January 2018 and December 2021. Opioid use was defined as administration of opioid analgesics for pain control within 30 days before or after pembrolizumab initiation. Stabilized inverse probability of treatment weighting (IPTW) using propensity scores was applied to adjust for baseline imbalances and evaluate outcomes.Results: Of 76 recruited patients, 68 were eligible. In IPTW-weighted Cox regression analyses, opioid use was associated with shorter progression-free survival (median 6.7 vs. 4.1 months; hazard ratio [HR] 2.85, 95% confidence interval [CI] 1.67-4.88; p < 0.001) and overall survival (18.9 vs. 6.9 months; HR 4.06, 95% CI 1.73-9.55; p = 0.001).Conclusion: Opioid use was associated with worse pembrolizumab outcomes in urothelial carcinoma, suggesting the need for careful, clinically appropriate opioid use during treatment.","PeriodicalId":13328,"journal":{"name":"Immunotherapy","volume":" ","pages":"657-664"},"PeriodicalIF":2.3,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13592114/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148445611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0